Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization for HEPLISAV B, a two-dose adult hepatitis B vaccine, in Great Britain. The approval is based on positive safety and immunogenicity results from three Phase 3 clinical trials. HEPLISAV B is designed to provide active immunization against various subtypes of hepatitis B virus in adults aged 18 and older, marking a significant advancement in hepatitis B prevention. Dynavax aims to engage potential commercial partners for distribution in Great Britain.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported a strong financial performance for 2022, with total revenue reaching $723 million, a 64% increase from $439 million in 2021. The net revenue from HEPLISAV-B® vaccine was $126 million, up 104% year-over-year, while CpG 1018® adjuvant revenue hit $588 million. For 2023, the company expects HEPLISAV-B revenue between $165 million and $185 million, reflecting a 30-47% growth. The company ended the year with a robust cash position of $624 million.
Dynavax is well-positioned to capture a larger market share in the expanding adult hepatitis B vaccination landscape.
Dynavax Technologies Corporation (Nasdaq: DVAX) is set to announce its fourth quarter and full year 2022 financial results on February 23, 2023, after the U.S. market closes. A conference call will follow at 4:30 p.m. ET. Investors can access the live audio webcast through the company's website. Dynavax focuses on developing and commercializing innovative vaccines. Its notable products include HEPLISAV-B for Hepatitis B prevention and CpG 1018, used in various COVID-19 vaccines. The company aims to advance its position through global collaborations.
Dynavax Technologies Corporation announced its uplisting to the Nasdaq Global Select Market, effective January 31, 2023. This upgrade reflects the company's strong growth and adherence to strict financial standards. CEO Ryan Spencer stated that this advancement underscores the company's execution excellence and commitment to public health through innovative vaccines. Dynavax is recognized for its commercial products, including HEPLISAV-B, a hepatitis B vaccine, and CpG 1018, an adjuvant used in multiple COVID-19 vaccines. The Nasdaq Global Select Market includes over 1,700 stocks meeting rigorous corporate governance and financial requirements.
Dynavax Technologies (DVAX) reported strong preliminary financial results for the year ending December 31, 2022. HEPLISAV-B vaccine's net product revenue reached approximately $126 million, marking a 104% growth year-over-year. The CpG 1018 adjuvant generated about $588 million in revenue. The company maintained a robust cash position with approximately $624 million in cash and investments. Additionally, topline results from the Phase 1 shingles trial indicated favorable tolerability and promising vaccine response rates compared to the comparator vaccine, Shingrix®.
Dynavax Technologies (Nasdaq: DVAX) announced its participation in two investor conferences, highlighting its role in developing innovative vaccines. The presentations will include a fireside chat at the Guggenheim Healthcare Talks on November 14, 2022, at 10:10 a.m. EST and another at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:05 a.m. EST. Investors can access live webcasts through the Company's website's 'Events & Presentations' section. Dynavax specializes in products like HEPLISAV-B and the CpG 1018 adjuvant.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported Q3 2022 total revenue of $167.7 million, reflecting a 55% increase from $108.3 million in Q3 2021. HEPLISAV-B® vaccine revenue reached $37.5 million, up 65% year-over-year, while CpG 1018® adjuvant revenue was $126.3 million, a 50% rise. The company reaffirmed its full-year guidance for CpG 1018 revenue between $550 million and $600 million. Notably, Dynavax anticipates a second consecutive year of profitability, with a reported GAAP net income of $63.8 million for the quarter.
Dynavax Technologies Corporation (Nasdaq: DVAX) is set to report its third quarter financial results on November 3, 2022, post-market close. The company will also host a conference call at 4:30 p.m. ET. Both the call and a following audio webcast will be accessible on Dynavax's investor relations page. Dynavax specializes in developing vaccines, notably its approved products, HEPLISAV-B and the CpG 1018 adjuvant, which is instrumental in various COVID-19 vaccine formulations. More details are available on the company’s website.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 10:00 a.m. P.T.. This presentation will be available via webcast on the company's website under the 'Events & Presentations' section. Dynavax focuses on innovative vaccines, with two commercial products: HEPLISAV-B and CpG 1018 adjuvant, aimed at preventing hepatitis B and enhancing various vaccines, respectively.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced the dosing of the first participant in a Phase 2 clinical trial for the adjuvanted plague vaccine, developed in collaboration with the U.S. Department of Defense. This trial evaluates the immunogenicity and safety of the recombinant plague vaccine combined with Dynavax's CpG 1018 adjuvant. The funding for this initiative is approximately $22 million over two and a half years. The trial aims to assess a two-dose regimen over one month, potentially shortening the standard three-dose schedule. The CpG 1018 adjuvant has previously shown safety in various vaccines.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
